Alterity Therapeutics Limited (ATH.AX)
AUD 0.01
(14.29%)
AUD 0.01
(14.29%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -19.6 Million AUD | -33.93% |
| 2023 | -14.63 Million AUD | 5.59% |
| 2022 | -15.5 Million AUD | -2.13% |
| 2021 | -15.17 Million AUD | -45.75% |
| 2020 | -10.41 Million AUD | 18.09% |
| 2019 | -12.71 Million AUD | -63.62% |
| 2018 | -7.77 Million AUD | -12.91% |
| 2017 | -6.88 Million AUD | 19.86% |
| 2016 | -8.58 Million AUD | 17.72% |
| 2015 | -10.43 Million AUD | 16.86% |
| 2014 | -12.55 Million AUD | -60.89% |
| 2013 | -7.8 Million AUD | -46.69% |
| 2012 | -5.31 Million AUD | 15.27% |
| 2011 | -6.27 Million AUD | -28.08% |
| 2010 | -4.9 Million AUD | 40.87% |
| 2009 | -8.28 Million AUD | 34.91% |
| 2008 | -12.73 Million AUD | -15.86% |
| 2007 | -10.99 Million AUD | 3.71% |
| 2006 | -11.41 Million AUD | 3.34% |
| 2005 | -11.8 Million AUD | -32.82% |
| 2004 | -8.88 Million AUD | -134.4% |
| 2003 | -3.79 Million AUD | 24.08% |
| 2002 | -4.99 Million AUD | -66.47% |
| 2001 | -3 Million AUD | -774.45% |
| 2000 | -343.17 Thousand AUD | -328.97% |
| 1999 | -80 Thousand AUD | -11494.2% |
| 1998 | -690.00 AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q4 | -15.1 Million AUD | 0.0% |
| 2024 FY | -23.62 Million AUD | -61.39% |
| 2024 Q2 | -8.51 Million AUD | 0.0% |
| 2023 FY | -14.63 Million AUD | 5.59% |
| 2023 Q4 | -7.77 Million AUD | 0.0% |
| 2023 Q2 | -10.74 Million AUD | 0.0% |
| 2022 Q4 | -10.46 Million AUD | 0.0% |
| 2022 Q2 | -10.16 Million AUD | 0.0% |
| 2022 FY | -15.5 Million AUD | -2.13% |
| 2021 FY | -15.17 Million AUD | -45.75% |
| 2021 Q4 | -9.87 Million AUD | 0.0% |
| 2021 Q2 | -9.64 Million AUD | 0.0% |
| 2020 Q1 | -2.89 Million AUD | 75.19% |
| 2020 FY | -10.41 Million AUD | 18.09% |
| 2020 Q2 | -7.59 Million AUD | -162.78% |
| 2020 Q3 | -4.07 Million AUD | 46.38% |
| 2020 Q4 | -6.28 Million AUD | -54.36% |
| 2019 Q3 | -3.59 Million AUD | 35.87% |
| 2019 Q1 | -2.8 Million AUD | 45.99% |
| 2019 Q4 | -11.65 Million AUD | -224.17% |
| 2019 FY | -12.71 Million AUD | -63.62% |
| 2019 Q2 | -5.6 Million AUD | -100.0% |
| 2018 Q3 | -2.59 Million AUD | 13.69% |
| 2018 Q2 | -3 Million AUD | -100.0% |
| 2018 FY | -7.77 Million AUD | -12.91% |
| 2018 Q4 | -5.18 Million AUD | -100.0% |
| 2018 Q1 | -1.5 Million AUD | 45.02% |
| 2017 Q1 | -2.07 Million AUD | 53.0% |
| 2017 Q3 | -1.36 Million AUD | 67.04% |
| 2017 Q2 | -4.14 Million AUD | -100.0% |
| 2017 FY | -6.88 Million AUD | 19.86% |
| 2017 Q4 | -2.73 Million AUD | -100.0% |
| 2016 Q4 | -4.41 Million AUD | -100.0% |
| 2016 Q2 | -4.17 Million AUD | -100.0% |
| 2016 Q3 | -2.2 Million AUD | 47.14% |
| 2016 Q1 | -2.08 Million AUD | 65.7% |
| 2016 FY | -8.58 Million AUD | 17.72% |
| 2015 FY | -10.43 Million AUD | 16.86% |
| 2015 Q2 | -4.52 Million AUD | -100.0% |
| 2015 Q3 | -3.04 Million AUD | 32.73% |
| 2015 Q4 | -6.08 Million AUD | -100.0% |
| 2015 Q1 | -2.26 Million AUD | 51.74% |
| 2014 Q2 | -7.83 Million AUD | -100.0% |
| 2014 FY | -12.55 Million AUD | -60.89% |
| 2014 Q3 | -2.34 Million AUD | 70.11% |
| 2014 Q1 | -3.91 Million AUD | -8.75% |
| 2014 Q4 | -4.68 Million AUD | -100.0% |
| 2013 Q3 | -1.8 Million AUD | 56.91% |
| 2013 Q4 | -3.6 Million AUD | -100.0% |
| 2013 Q1 | -2.09 Million AUD | 0.0% |
| 2013 FY | -7.8 Million AUD | -46.69% |
| 2013 Q2 | -4.18 Million AUD | -100.0% |
| 2012 FY | -5.31 Million AUD | 15.27% |
| 2011 FY | -6.27 Million AUD | -28.08% |
| 2010 FY | -4.9 Million AUD | 40.87% |
| 2009 FY | -8.28 Million AUD | 34.91% |
| 2008 Q1 | 127 Thousand AUD | 101.12% |
| 2008 FY | -12.73 Million AUD | -15.86% |
| 2008 Q4 | -13.1 Million AUD | -11144.72% |
| 2008 Q3 | 118.66 Thousand AUD | 103.19% |
| 2008 Q2 | -3.71 Million AUD | -3026.35% |
| 2007 FY | -10.99 Million AUD | 3.71% |
| 2007 Q4 | -11.36 Million AUD | -8504.24% |
| 2007 Q3 | 135.2 Thousand AUD | 103.64% |
| 2007 Q2 | -3.71 Million AUD | -3237.39% |
| 2007 Q1 | 118.3 Thousand AUD | 100.99% |
| 2006 Q3 | 190.67 Thousand AUD | 106.43% |
| 2006 Q2 | -2.96 Million AUD | -1463.8% |
| 2006 Q1 | 217.29 Thousand AUD | 101.57% |
| 2006 FY | -11.41 Million AUD | 3.34% |
| 2006 Q4 | -11.98 Million AUD | -6385.63% |
| 2005 Q3 | 637 Thousand AUD | 125.61% |
| 2005 Q4 | -13.82 Million AUD | -2270.86% |
| 2005 FY | -11.8 Million AUD | -32.82% |
| 2005 Q2 | -2.48 Million AUD | -463.44% |
| 2005 Q1 | 684.35 Thousand AUD | 106.46% |
| 2004 Q4 | -10.59 Million AUD | -1853.18% |
| 2004 Q1 | 561.87 Thousand AUD | 111.7% |
| 2004 FY | -8.88 Million AUD | -134.4% |
| 2004 Q3 | 604.41 Thousand AUD | 130.97% |
| 2004 Q2 | -1.95 Million AUD | -447.36% |
| 2003 Q4 | -4.8 Million AUD | -936.43% |
| 2003 Q1 | 242.4 Thousand AUD | 0.0% |
| 2003 Q2 | -1.56 Million AUD | -747.46% |
| 2003 FY | -3.79 Million AUD | 24.08% |
| 2003 Q3 | 574.13 Thousand AUD | 136.58% |
| 2002 FY | -4.99 Million AUD | -66.47% |
| 2001 FY | -3 Million AUD | -774.45% |
| 2000 FY | -343.17 Thousand AUD | -328.97% |
| 1999 FY | -80 Thousand AUD | -11494.2% |
| 1998 FY | -690.00 AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AdAlta Limited | -5.26 Million AUD | -272.543% |
| Acrux Limited | -9.83 Million AUD | -99.326% |
| Actinogen Medical Limited | -12.83 Million AUD | -52.673% |
| AnteoTech Limited | -11.72 Million AUD | -67.156% |
| Argenica Therapeutics Limited | -5.67 Million AUD | -245.636% |
| Arovella Therapeutics Limited | -7.19 Million AUD | -172.509% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -1243.386% |
| Amplia Therapeutics Limited | -4.42 Million AUD | -342.979% |
| Avecho Biotechnology Limited | -4.58 Million AUD | -327.128% |
| Bio-Gene Technology Limited | -3.06 Million AUD | -540.064% |
| Biome Australia Limited | -1.91 Million AUD | -924.53% |
| Biotron Limited | -5.15 Million AUD | -280.529% |
| Botanix Pharmaceuticals Limited | -14.69 Million AUD | -33.346% |
| BTC Health Limited | 1.05 Million AUD | 1957.477% |
| Chimeric Therapeutics Limited | -12.3 Million AUD | -59.238% |
| CSL Limited | 5.64 Billion AUD | 100.347% |
| Clarity Pharmaceuticals Ltd | -44.8 Million AUD | 56.247% |
| Clinuvel Pharmaceuticals Limited | 49.14 Million AUD | 139.883% |
| Cynata Therapeutics Limited | -8.8 Million AUD | -122.546% |
| Dimerix Limited | -25.05 Million AUD | 21.78% |
| EZZ Life Science Holdings Limited | 9.71 Million AUD | 301.735% |
| Hexima Limited | -1 Million AUD | -1843.168% |
| Island Pharmaceuticals Limited | -2.87 Million AUD | -582.088% |
| Immuron Limited | -5.8 Million AUD | -237.895% |
| Immutep Limited | -44.93 Million AUD | 56.38% |
| Imugene Limited | -140.93 Million AUD | 86.091% |
| Invex Therapeutics Ltd | -2.13 Million AUD | -818.704% |
| Memphasys Limited | -2.7 Million AUD | -624.915% |
| Nanollose Limited | -1.24 Million AUD | -1468.356% |
| Neuren Pharmaceuticals Limited | 225.96 Million AUD | 108.675% |
| Noxopharm Limited | -7.53 Million AUD | -160.142% |
| NeuroScientific Biopharmaceuticals Limited | -2.05 Million AUD | -853.131% |
| Nyrada Inc. | -4.56 Million AUD | -329.831% |
| Orthocell Limited | -11.68 Million AUD | -67.807% |
| PharmAust Limited | -6.65 Million AUD | -194.381% |
| Patrys Limited | -3.53 Million AUD | -453.854% |
| Paradigm Biopharmaceuticals Limited | -65.11 Million AUD | 69.895% |
| Proteomics International Laboratories Limited | -7.23 Million AUD | -171.058% |
| Prescient Therapeutics Limited | -7.18 Million AUD | -172.76% |
| PYC Therapeutics Limited | -38.85 Million AUD | 49.555% |
| Race Oncology Limited | -13.38 Million AUD | -46.494% |
| Radiopharm Theranostics Limited | -47.2 Million AUD | 58.48% |
| Recce Pharmaceuticals Ltd | -22.05 Million AUD | 11.108% |
| Starpharma Holdings Limited | -15.15 Million AUD | -29.307% |
| Telix Pharmaceuticals Limited | - AUD | Infinity% |
| Tissue Repair Ltd | -4.87 Million AUD | -302.008% |
| Zelira Therapeutics Limited | -5.93 Million AUD | -230.093% |